Treatment of myasthenia gravis with pyridostigmine.
D000279:Administration, Cutaneous; D000328:Adult; D005260:Female; D006801:Humans; D009157:Myasthenia Gravis / Q000188:drug therapy*; D011729:Pyridostigmine Bromide / Q000009:adverse effects* / Q000627:therapeutic use; D012601:Scopolamine / Q000008:administration & dosage*
D012601:Scopolamine; D011729:Pyridostigmine Bromide